Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 29 May 2025
Reviewer's report:
significant improved after revising , only one minor suggestion to enhance clarity and depth: in
the Results, briefly comment on the consistency of infliximab dosing schedules across the RCTs
and whether any dose–response trends emerged; and consider citing Niu C, Zhang J, Napel M,
Boppana LK, Anas H, Jadhav N, Dunnigan K, Okolo 3rd PI. Systematic review with meta-
analysis: Efficacy and safety of Upadacitinib in managing moderate-to-severe Crohn’s disease
and ulcerative colitis. Clinical Drug Investigation. 2024 Jun;44(6):371–85.
Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 29 May 2025
Reviewer's report:
significant improved after revising , only one minor suggestion to enhance clarity and depth: in
the Results, briefly comment on the consistency of infliximab dosing schedules across the RCTs
and whether any dose–response trends emerged; and consider citing Niu C, Zhang J, Napel M,
Boppana LK, Anas H, Jadhav N, Dunnigan K, Okolo 3rd PI. Systematic review with meta-
analysis: Efficacy and safety of Upadacitinib in managing moderate-to-severe Crohn’s disease
and ulcerative colitis. Clinical Drug Investigation. 2024 Jun;44(6):371–85.
Please review this paper.
user
Title: Infliximab for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated
Meta-Analysis of Randomized Controlled Trials
Version: 3 Date: 29 May 2025
Reviewer's report:
significant improved after revising , only one minor suggestion to enhance clarity and depth: in
the Results, briefly comment on the consistency of infliximab dosing schedules across the RCTs
and whether any dose–response trends emerged; and consider citing Niu C, Zhang J, Napel M,
Boppana LK, Anas H, Jadhav N, Dunnigan K, Okolo 3rd PI. Systematic review with meta-
analysis: Efficacy and safety of Upadacitinib in managing moderate-to-severe Crohn’s disease
and ulcerative colitis. Clinical Drug Investigation. 2024 Jun;44(6):371–85.
assistant